UCB SA (OTCMKTS:UCBJY) Sees Large Growth in Short Interest

UCB SA (OTCMKTS:UCBJY) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,600 shares, an increase of 1,200.0% from the March 31st total of 200 shares. Based on an average daily trading volume, of 24,200 shares, the days-to-cover ratio is currently 0.1 days.

UCB Trading Down 0.1 %

Shares of UCBJY stock traded down $0.10 during trading hours on Friday, hitting $66.48. 36,784 shares of the company’s stock were exchanged, compared to its average volume of 12,573. The firm has a 50 day moving average of $59.68 and a two-hundred day moving average of $48.03. UCB has a fifty-two week low of $34.85 and a fifty-two week high of $67.30.

UCB Cuts Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 29th will be paid a dividend of $0.4574 per share. This represents a dividend yield of 0.71%. The ex-dividend date is Friday, April 26th. UCB’s payout ratio is 46.55%.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.